Chlamydia Drug Development Pipeline Study, H2 2018
Chlamydia Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Chlamydia pipeline products.
DISEASE OVERVIEW
Chlamydia infections are caused by Chlamydia trachomatis bacteria. Worldwide, the annual prevalence of the sexually transmitted infection (STD) is estimated to be over 100 million. As limited or no symptoms are presented in initial period, the Chlamydia patients go for treatment in late stages. Amidst lack of vaccines available for prevention of the Chlamydia infection, 10 companies are actively developing the Chlamydia Infection pipeline drugs. Both genders are equally infected by the disease. In women, reproductive system can be infected, resulting in permanent damages and premature deliveries. Antibiotics are mainly given to patients who are infected by the disease.
Abera Bioscience AB, BlueWillow Biologics, Evofem Biosciences Inc, Genetic Immunity Inc, Genocea Biosciences, Lead Discovery Center GmbH, Melinta Therapeutics, Prokarium Ltd, QureTech Bio AB, and Vault Pharma Inc are actively investing their R&D efforts in development of vaccines and treatment solutions for Chlamydia infections.
REPORT DESCRIPTION
The Chlamydia pipeline guide presents complete overview of drugs currently being developed for Chlamydia. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).
Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Chlamydia pipeline candidate.
Research and Development progress along with latest news related to each of the Chlamydia pipeline candidates is included.
Major companies participating in therapeutic development of Chlamydia are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.
Amid strong interest for cure of Chlamydia from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Chlamydia clinical and pre-clinical products.
The report assists in identifying potential upcoming companies and drugs in Chlamydia pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.
SCOPE OF CHLAMYDIA PIPELINE REPORT INCLUDES
DISEASE OVERVIEW
Chlamydia infections are caused by Chlamydia trachomatis bacteria. Worldwide, the annual prevalence of the sexually transmitted infection (STD) is estimated to be over 100 million. As limited or no symptoms are presented in initial period, the Chlamydia patients go for treatment in late stages. Amidst lack of vaccines available for prevention of the Chlamydia infection, 10 companies are actively developing the Chlamydia Infection pipeline drugs. Both genders are equally infected by the disease. In women, reproductive system can be infected, resulting in permanent damages and premature deliveries. Antibiotics are mainly given to patients who are infected by the disease.
Abera Bioscience AB, BlueWillow Biologics, Evofem Biosciences Inc, Genetic Immunity Inc, Genocea Biosciences, Lead Discovery Center GmbH, Melinta Therapeutics, Prokarium Ltd, QureTech Bio AB, and Vault Pharma Inc are actively investing their R&D efforts in development of vaccines and treatment solutions for Chlamydia infections.
REPORT DESCRIPTION
The Chlamydia pipeline guide presents complete overview of drugs currently being developed for Chlamydia. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).
Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Chlamydia pipeline candidate.
Research and Development progress along with latest news related to each of the Chlamydia pipeline candidates is included.
Major companies participating in therapeutic development of Chlamydia are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.
Amid strong interest for cure of Chlamydia from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Chlamydia clinical and pre-clinical products.
The report assists in identifying potential upcoming companies and drugs in Chlamydia pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.
SCOPE OF CHLAMYDIA PIPELINE REPORT INCLUDES
- Panorama of Chlamydia pipeline markets including statistics on therapeutic drugs and companies involved
- Chlamydia Pipeline candidates across various development phases including both pre-clinical, discovery and clinical stages are covered
- Chlamydia pipeline candidates across various ‘Mechanism of Actions’ are also presented in the study
- Overview of companies participating in Chlamydia pipeline with short introduction to their businesses and pipeline projects
- For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.
- Research and Development progress and trial details, results wherever available, are also included in the pipeline study
- The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Chlamydia pipeline therapeutics
- Get clear understanding of the entire Chlamydia pipeline, with details on active projects
- Get in detail information of each product with updated information on each project along with key milestones
- Know the list of companies participating in global Chlamydia pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
- Get trial information for each pipeline product under development
- Understand the pipeline structure in terms of mechanism of Action, phase and company
I. KEY FINDINGS
1. Companies Investing in Chlamydia Pipeline include-
Number of Companies with Chlamydia projects in pre-clinical Development-
Number of Companies with Chlamydia projects in Clinical Development-
Chlamydia Pipeline Companies based in Americas
Chlamydia Pipeline Companies based in Europe
Chlamydia Pipeline Companies based in Asia Pacific
Chlamydia Pipeline Companies based in Rest of the World
2. Pipeline Candidates include-
Chlamydia Pipeline Agents in pre- clinical/Discovery stage of Development
Chlamydia Pipeline Agents in Clinical Development stage
Chlamydia Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs-
Small molecules among the Chlamydia Pipeline agents
II. INSIGHTS INTO CHLAMYDIA PIPELINE
1. Disease Overview
Introduction to Chlamydia
Symptoms and Causes of Chlamydia
Treatment or Prevention Options for Chlamydia
Other Details
2. Phase wise Pipeline Compounds
Chlamydia Pipeline- Pre- Clinical/Discovery stage Drugs
Chlamydia Pipeline- Phase 1 stage Drugs
Chlamydia Pipeline- Phase 2 stage Drugs
Chlamydia Pipeline- Phase 3 stage Drugs
Chlamydia Pipeline- Pre-Registration stage Drugs
3. Company wise Chlamydia Pipeline Compounds
4. Chlamydia Pipeline by Mechanism of Action
III. CHLAMYDIA PIPELINE COMPOUND DETAILS
Ab03
NE based chlamydia vaccine
Amphora
Chlamyderm
Chlamydia trachomatis vaccine
drug for Chlamydia Infections
solithromycin
Chlamydia trachomatis vaccine
drug for Chlamydia Infections(Virulence blockers)
VPI-201
Drug Details
1. Snapshot
Name of the Therapeutic Agent
Originator
Developing Company
Co-Developer/License Partner
Orphan Drug/Fast Track/Designation
Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details
IV. CHLAMYDIA PIPELINE COMPANY BRIEFS
Abera Bioscience AB
BlueWillow Biologics Inc
Evofem Biosciences Inc
Genetic Immunity Inc
Genocea Biosciences Inc
Lead Discovery Center GmbH
Melinta Therapeutics Inc
Prokarium Ltd
QureTech Bio AB
Vault Pharma Inc
V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL CHLAMYDIA PIPELINE MARKET
VI. APPENDIX
1. Publisher’s Expertise
2. Research Methodology
3. Contact Information
Some of the sections depicted above may be removed or modified on the basis of information availability
1. Companies Investing in Chlamydia Pipeline include-
Number of Companies with Chlamydia projects in pre-clinical Development-
Number of Companies with Chlamydia projects in Clinical Development-
Chlamydia Pipeline Companies based in Americas
Chlamydia Pipeline Companies based in Europe
Chlamydia Pipeline Companies based in Asia Pacific
Chlamydia Pipeline Companies based in Rest of the World
2. Pipeline Candidates include-
Chlamydia Pipeline Agents in pre- clinical/Discovery stage of Development
Chlamydia Pipeline Agents in Clinical Development stage
Chlamydia Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs-
Small molecules among the Chlamydia Pipeline agents
II. INSIGHTS INTO CHLAMYDIA PIPELINE
1. Disease Overview
Introduction to Chlamydia
Symptoms and Causes of Chlamydia
Treatment or Prevention Options for Chlamydia
Other Details
2. Phase wise Pipeline Compounds
Chlamydia Pipeline- Pre- Clinical/Discovery stage Drugs
Chlamydia Pipeline- Phase 1 stage Drugs
Chlamydia Pipeline- Phase 2 stage Drugs
Chlamydia Pipeline- Phase 3 stage Drugs
Chlamydia Pipeline- Pre-Registration stage Drugs
3. Company wise Chlamydia Pipeline Compounds
4. Chlamydia Pipeline by Mechanism of Action
III. CHLAMYDIA PIPELINE COMPOUND DETAILS
Ab03
NE based chlamydia vaccine
Amphora
Chlamyderm
Chlamydia trachomatis vaccine
drug for Chlamydia Infections
solithromycin
Chlamydia trachomatis vaccine
drug for Chlamydia Infections(Virulence blockers)
VPI-201
Drug Details
1. Snapshot
Name of the Therapeutic Agent
Originator
Developing Company
Co-Developer/License Partner
Orphan Drug/Fast Track/Designation
Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details
IV. CHLAMYDIA PIPELINE COMPANY BRIEFS
Abera Bioscience AB
BlueWillow Biologics Inc
Evofem Biosciences Inc
Genetic Immunity Inc
Genocea Biosciences Inc
Lead Discovery Center GmbH
Melinta Therapeutics Inc
Prokarium Ltd
QureTech Bio AB
Vault Pharma Inc
V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL CHLAMYDIA PIPELINE MARKET
VI. APPENDIX
1. Publisher’s Expertise
2. Research Methodology
3. Contact Information
Some of the sections depicted above may be removed or modified on the basis of information availability
